Thomson Healthcare Online Treatment Tools Mark Milestone

Thomson HealthcareMore than one million people have used Thomson Healthcare (NYSE: TOC; TSX: TOC) Profiler treatment option tools to help make treatment decisions for cancer, heart disease and lung disease. "When you consider more than 20 million people are diagnosed with cancer, heart disease or lung disease each year, this is not the kind of milestone one celebrates," said Alicia Moffat, Thomson Healthcare's vice president of Web operations. "It is a significant indicator of the persistence of these conditions in our country and a positive sign that patients and caregivers are taking a proactive approach to disease education, management and treatment."

The tools are unique in their approach to helping people understand their conditions, their possible treatments and the side effects of those treatments. The online Profiler tools are free of charge and accessible under the "treatment decision" links on the American Cancer Society, American Heart Association, and American Lung Association Web sites.

The Thomson Healthcare Profiler tools walk users through a step-by-step approach to a better understanding of their diagnostic tests, treatment options and, in some cases, possible outcomes based on similar people treated within clinical trials. All of the information presented is based on clinical evidence published in leading medical journals. No other Internet offering produces such in-depth treatment information tailored to an individual's clinical status.

Donald Distasio, chief executive officer, Eastern Division of the American Cancer Society and a prostate cancer survivor, says that - even though he was aware of the tools and other information available at the American Cancer Society's cancer.org Web site - he didn't really appreciate the value of knowing his options until he was faced with making those tough treatment decisions for himself.

"There is just an extraordinary depth of information there. Prostate cancer has rather difficult treatment choices to make, and the tool and all the information on the cancer.org site was very reassuring and helpful," Distasio said. "With these tools and information on cancer.org, I felt very comfortable. All my questions had been answered and that makes a world of difference in how you feel going into treatment."

About Thomson Healthcare
Thomson Healthcare is the leading provider of decision support solutions that help organizations across the healthcare industry improve clinical and business performance. Thomson Healthcare products and services help clinicians, hospitals, employers, health plans, government agencies, and pharmaceutical companies manage the cost and improve the quality of healthcare.

Thomson Healthcare is a part of The Thomson Corporation, a provider of value-added information, software tools and applications to professionals in the fields of healthcare, law, tax, accounting, scientific research, and financial services. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC). For more information, visit www.thomsonhealthcare.com.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...